Real World Efficacy and Safety of First Line Chemo Immunotherapy in Extensive Stage Small Cell Lung Cancer and its association with molecular subtype

Miran Han(Samsung Medical Center), Myung‐Ju Ahn(Sungkyunkwan University), Junkyu Kim(Samsung Medical Center), Jin Seok Ahn(Chungnam National University), Jin‐Yong Kim(Samsung Medical Center), Jong‐Mu Sun(Samsung Medical Center), Sehhoon Park(Samsung Medical Center), Se‐Hoon Lee(Samsung Medical Center)
Cancer Research and Treatment
November 5, 2025
10.4143/crt.2025.971
Cited by 0

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k